Status:
COMPLETED
Botulinum Toxin to Avoid Component Separation in Midline Large Hernias
Lead Sponsor:
Hospital Universitario La Fe
Conditions:
Botulinum Toxin Type A
Rives Repair
Eligibility:
All Genders
Phase:
NA
Brief Summary
Introduction. The goal of our study was to compare results in patients with large midline incisional hernia (LMIH) using only anterior compònent separation (CST) versus preoperative botulinum toxin (B...
Detailed Description
Multiple techniques have been described to decrease tension in the closure of the hernia defect in the large midline incisional hernias (LMIH) (1). Anterior component separation (CST) has demonstrated...
Eligibility Criteria
Inclusion
- patients with LMIH with hernia transverse defect between 12 and 18 cms in preoperative CT scan
- grade W3 in EHS classification
Exclusion
- patients with loss of domain hernia (Tanaka index over 20% in CT scan)
- laparoscopic approaches
- hernias not involving the midline, such as isolated flank and parastomal defects.
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04131348
Start Date
December 1 2016
End Date
October 1 2019
Last Update
October 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jose Bueno-Lledo
Valencia, Spain, 46008